The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics

• Published in: Journal of headache and pain 2023-06, Vol.24 (1), p.70-70, Article 70
• Main Authors: Karlsson, William Kristian, Ashina, Håkan, Cullum, Christopher Kjær, Christensen, Rune Häckert, Al-Khazali, Haidar Muhsen, Amin, Faisal Mohammad, Ashina, Messoud
• Format: Article
• Language: English
• Subjects: Adult; Biochemistry; Biomarker; Biomarkers; Brain mapping; Calcitonin; Calcitonin Gene-Related Peptide; CGRP; Clinical outcomes; Demography; Erenumab; Female; Functional magnetic resonance imaging; Headache; Humans; Internal Medicine; Intravenous administration; Longitudinal Studies; Magnetic resonance imaging; Male; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - diagnostic imaging; Migraine Disorders - drug therapy; Migraine Disorders - epidemiology; Monoclonal antibodies; Neuroimaging; Neurology; Pain Medicine; Patients; Population studies; Predictors; Prospective Studies; Registries; Structure-function relationships
• ISSN: 1129-2377; 1129-2369; 1129-2377
• DOI: 10.1186/s10194-023-01604-2

Background Erenumab has demonstrated effectiveness for prevention of migraine attacks, but the treatment is costly, and a considerable proportion of patients do not respond to it. The Registry for Migraine study (REFORM) was initiated to discover biomarkers that can predict response to erenumab in patients with migraine. The specific objective was to investigate differences in erenumab efficacy based on clinical information, blood-based biomarkers, structural and functional magnetic resonance imaging (MRI), and response to intravenous infusion of calcitonin gene-related peptide (CGRP). In this first report of the REFORM study, we provide a comprehensive description of the study methodology, and present the baseline characteristics of the study population. Methods The REFORM study was a single-center, prospective, longitudinal cohort study in adults with migraine who were scheduled to receive preventive treatment with erenumab as part of a separate, open-label, single-arm phase IV trial. The study included four periods: a 2-week screening period (Weeks -6 to -5), 4-week baseline period (Week -4 to Day 1), 24-week treatment period (Day 1 to Week 24), and a 24-week follow-up period without treatment (Week 25 to Week 48). Demographic and clinical characteristics were recorded using a semi-structured interview, whilst outcome data were obtained using a headache diary, patient-reported outcomes, blood sampling, brain MRI, and responsiveness to intravenous infusion of CGRP. Results The study enrolled 751 participants, with a mean age ± SD of 43.8 ± 12.2 years, of which 88.8% ( n  = 667) were female. At enrollment, 64.7% ( n  = 486) were diagnosed with chronic migraine, and 30.2% ( n  = 227) had history of aura. The mean monthly migraine days (MMDs) was 14.5 ± 7.0. Concomitant preventive medications were used by 48.5% ( n  = 364) of the participants, and 39.9% ( n  = 300) had failed ≥ 4 preventive medications. Conclusion The REFORM study enrolled a population with a high migraine burden and frequent use of concomitant medications. The baseline characteristics were representative of patients with migraine in specialized headache clinics. Future publications will report the results of the investigations presented in this article. Trial registration The study and sub-studies were registered on ClinicalTrials.gov (NCT04592952; NCT04603976; and NCT04674020).